NEIMETH - Neimeth International Pharma
Neimeth International Pharmaceuticals Plc is the resultant company from the management-buy-out of the 60% equity holding of Pfizer Inc. in Pfizer Products Plc. This management-buy-out took place in May 1997 when Pfizer Inc., in pursuit of its global repositioning strategy, divested 60% equity in Pfizer Products Plc. in favour of the existing management. Before the brand name Neimeth International Pharmaceuticals Plc, the company had operated in Nigeria for 40 years, manufacturing, marketing, and distributing Pfizer brands of pharmaceutical and veterinary products in tablets, capsules, ointment/cream, powder, injectables, and oral liquid forms.
|Last Trading Results||Growth & Valuation|
|Opening Price:||0.40||Earnings Per Share:||--|
|Day's Low Price:||--||Price/Earning Ratio:||--|
|Day's High Price:||--||Dividend Per Share:||--|
|Traded Volume:||17,944||Dividend Yield:||--|
|Number of Deals:||3||Shares Outstanding:||1.9b|
NEIMETH Stock Market Performance
The stock of Neimeth International Pharma (NEIMETH) is currently trading at 0.40 NGN per share on the Nigerian Stock Exchange. NEIMETH began the year with a share price of 0.78 NGN but has since lost 48.72% off that price valuation, ranking it 157th on the NSE in terms of year-to-date performance. The table below details the last 10 trading days of activity of Neimeth International Pharma on the Nigerian Stock Exchange.
Profile of Neimeth International Pharma
Neimeth International Pharma operates in the Health Care sector. Unfortunately, we do not have information on the company's board of directors and/or key executives at this time.
|Factsheet of Neimeth International Pharma|
1 Henry Carr Street, Ikeja Industrial Estate, Ikeja, Lagos 21111, Nigeria
NEIMETH Industrial Market Competitors
Neimeth International Pharma, issuers of the NEIMETH stock on the Nigerian Stock Exchange, have a number of market competitors who are also engaged in the Health Care sector. The table below gives you an overview of the market standing of the top nine by year-to-date performance.
|Code||Name||Mkt. Cap.||L. Price||YearTD|
|EVANSMED||Evans Medical Plc||366.17m||0.50||+0.00%|
|MAYBAKER||May & Baker Nigeria||3.38b||1.96||-20.0%|
|GLAXOSMITH||Glaxo Smithkline Consumer||7.53b||6.30||-56.5%|